Clairvoyant Therapeutics Receives Approval in Canada to Initiate a World-leading Psilocybin Trial for Treatment of Alcohol Use Disorder

2 years ago

VANCOUVER, BC / ACCESSWIRE / January 20, 2022 / Clairvoyant Therapeutics, a Canadian biotech company focused on the development of…

Goodbody Health (Previously Sativa Wellness Group) Announces a New Sponsorship Agreement With James Hedley

2 years ago

VANCOUVER, BC / ACCESSWIRE / January 20, 2022 / Goodbody Health Inc. (CSE:GDBY) ("Goodbody Health" or the "Company") is pleased…

Icario Celebrates Year of Record Growth and Impact

2 years ago

Strong Company Momentum Advances Icario’s Mission of Making the World a Healthier PlaceMINNEAPOLIS, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Icario,…

Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection

2 years ago

Top-line data anticipated in the second quarter of 2022SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ:…

Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer

2 years ago

SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation…

Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

2 years ago

– Live video webcast presentation on Tuesday, January 25that 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) --…

Healthcare Triangle, Inc. Releases Shareholder Update

2 years ago

Highlights Market Opportunity and Recent Accretive Acquisition Awarded Top 100 Premier Partner Status at Amazon World Services & Premier Partner Status…

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

2 years ago

JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

2 years ago

BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics…

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors

2 years ago

SHANGHAI, China and SUZHOU, China and GERMANTOWN, Md., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global…